

February 26, 2016



Second Sight Mourns Loss and Celebrates Legacy of Founder Alfred E. Mann

SYLMAR, Calif.--(BUSINESS WIRE)-- [Second Sight Medical Products, Inc.](#) (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today mourns the passing of Founder Alfred E. Mann.

"We are all deeply saddened by the loss of our founder, mentor and friend, Al Mann, a pioneering leader whose contributions and vision profoundly impacted the lives of so many and whose legacy will impact many more. Everyone he came in contact with was enriched and inspired by him. Personally, I am eternally grateful for Al's generous guidance and support these last 16 years. At Second Sight, we all feel deeply honored to have worked alongside of and known such a remarkable person. The world is a little darker without his presence, but his spirit will live on in every blind person who is brought back into the light by our products," said Dr. Robert Greenberg, Chairman of Second Sight.

During his 70 year career, Alfred Mann founded 17 companies. Three companies became public and ten were acquired at an overall total of almost \$8 billion. Hundreds of thousands of people have benefitted from his technologies and he created thousands of jobs. The medical miracles produced by these companies included infusion and insulin pumps, pacemakers, cochlear implants, spinal cord stimulators and inhalable insulin, to name a few. He will be missed by all.

About Second Sight

Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed, and manufactures, the Argus® II Retinal Prosthesis intended to provide some useful vision to individuals with outer-retinal degenerations such as Retinitis Pigmentosa (RP). Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than those currently treated by Argus II or other therapies. U.S. Headquarters are in Sylmar, CA, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160226005314/en/>

For Second Sight:

Institutional Investors

In-Site Communications, Inc.

Lisa Wilson, 212-452-2793

President

lwilson@insitecony.com

or

Individual Investors

MZ North America

Greg Falesnik, 949-385-6449

Senior Vice President

greg.falesnik@mzgroup.us

Source: Second Sight Medical Products, Inc.